Nova One Advisor
Global Olanzapine Market Size, Share, Forecast Report, 2020-2027

Global Olanzapine Market Size, Share, Forecast Report, 2020-2027

Status: Published Category: Healthcare Insight Code: 2568 Format: PDF / PPT / Excel

Content

Olanzapine, formerly known as Zyprexa is a US Food and Drug administration approved drug used in the treatment of schizophrenia, bipolar disorder and other neurological disorders. Olanzapine is generic and is available under many trade names worldwide. Olanzapine is promoted in various nations, with tablets running from 2.5 to 20 milligrams. Zyprexa (and nonspecific olanzapine) is accessible as an orally-breaking down "wafer" which quickly disintegrates in spit. It is likewise accessible in 10 milligram vials for intramuscular infusion.

The market of Olanzapine has been evaluated as $XX million which includes the XX% of market share from Asia pacific followed by Europe. Olanzapine was firstly introduced in the Europe region in the year 1996 when the high amount of population was suffering from the neurological disorder diseases. China is the largest market for the Olanzapine drug and growing with the compound annual growth rate (CAGR) rate of more than 27% and expected to touch the CAGR of XX% in the forecasted period. Olanzapine has been very effective drug but it also has some negative aspects like agitation, dysarthria with others.
Global Olanzapine Market Report: Market Segmentation

For the better understanding of the topic, Global Olanzapine market report has been segmented on the basis of:

· Types

· Application

· Geography

Types of Olanzapine is been categorized as ZYPREXA tablets, ZYPREXA ZYDIS and ZYPREXA IntraMuscular which is available for injections. Olanzapine applications includes (Schizophrenia, Bipolar disorder, among others)

Global Olanzapine Market Report: Key Players

The key player in the global Olanzapine market includes:

  • WATSON Pharmaceuticals(Changzhou)
  • Hanson Pharmaceutical (Hanson Pharmaceutical has the biggest piece of the pie of around 44% for deals esteem in 2014)
  • Sandoz
  • Zhejiang Langhua Pharmaceuticals
  • Hansoh Pharmaceutical
  • Aurobindo Pharma
  • Jubilant Lifesciencest
  • Torrent Pharmaceuticals
  • Sun Pharmaceutical
  • Lilly
  • Dr. Reddy’s Laboratories
  • Mylan Pharmaceuticals
  • Apotex Inc.
  • Teva Pharmaceutical
  • Insight Code: 2568
  • No. of Pages: 250
  • Format: PDF/PPT/Excel
  • Published: July 2020
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034